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urea nitrogen was 64 mg/dl; serum creatinine, 1.8 mg/dl; total
cholesterol, 192 mg/dl; triglycerides, 180 mg/dl; LDL choles-
terol, 88 mg/dl; and HDL cholesterol, 36 mg/dl. A family study
of diabetic nephropathy involved the patient’s parents and a
sibling (Fig. 1).
Sister. The patient’s 43-year-old sister (not the organ donor)
had had IDDM for 33 years and had taken insulin since the
time of diagnosis. At the time of evaluation, she was 58 in. tall
and weighed 107 lb.; her maximum weight had been 127 lb. at
age 37. Her blood pressure was 108/60 mm Hg, and she was
taking 60 units of insulin daily. Her medical history was remark-
able only for hypothyroidism, for which she was treated with
oral thyroid replacement. She had no hypertension or renal,
ophthalmic, or cardiovascular disease. She has never smoked.
Recent laboratory results included a urine ACR of 3 mg/mg.
Her blood urea nitrogen was 19 mg/dl; serum creatinine, 0.9CASE PRESENTATION
mg/dl; total cholesterol, 190 mg/dl; triglycerides, 85 mg/dl; LDL
Proband. A 45-year-old man had had insulin-dependent di- cholesterol, 89 mg/dl; and HDL cholesterol, 65 mg/dl.
abetes mellitus (IDDM) for 36 years; he had used insulin since Father. At the time of evaluation, the proband’s father was
the time of initial diagnosis. At the time of evaluation he was 63 years old, 70 in. tall, and weighed 203 lb., which was his
69 in. tall and weighed 150 lb.; his maximum weight had been maximum weight. His blood pressure was 180/110 mm Hg.
180 lb. at age 40. He was taking 60 units of insulin daily, as well His medical history was significant for non-insulin-dependent
as enalapril, doxazosin, and metoprolol. His blood pressure was diabetes mellitus diagnosed 3 years ago and treated with gly-
150/60 mm Hg. Hypertension had been diagnosed 12 years ago. buride. Dyslipidemia, diagnosed 2 years ago, was treated with
End-stage renal disease, presumably of diabetic origin, necessi- gemfibrozil. Simultaneously, hypertension was diagnosed and
tated hemodialysis 11 years earlier. He received a renal trans- he began treatment with enalapril. He has had no other signs
plant from a non-hypertensive sister the following year. In or symptoms of cardiovascular disease. He quit smoking 30
view of the completeness of HLA matching, azathioprine was years ago. The blood urea nitrogen was 22 mg/dl; serum creati-
discontinued approximately one year later. He was treated nine, 1.4 mg/dl; total cholesterol, 249 mg/dl; triglycerides, 486
with panretinal photocoagulation 14 years ago for proliferative mg/dl; LDL cholesterol, 146 mg/dl; and HDL cholesterol, 34
diabetic retinopathy. Ten years ago, he suffered a myocardial mg/dl. An Albustix urine test was 21 positive.
infarction complicated by congestive heart failure. In the subse- Mother. The patient’s 64-year-old mother was in good health,
quent year, he underwent triple-vessel coronary artery bypass without diabetes, hypertension, or cardiovascular or renal dis-
grafting. Four years ago he had above-the-knee amputations ease. At the time of evaluation she was 59 in. tall and weighed
of both legs and has been confined to a wheelchair since. He 145 lb. Her blood pressure was 110/60 mm Hg. Her blood
has never smoked cigarettes and has no history of dyslipidemia. urea nitrogen was 6 mg/dl; serum creatinine, 0.6 mg/dl; total
Besides insulin and antihypertensive medications, he takes as- cholesterol, 334 mg/dl; triglycerides, 488 mg/dl; LDL choles-
pirin, isosorbide dinitrate, digoxin, prednisone, and furosemide. terol, 179 mg/dl; and HDL cholesterol, 30 mg/dl. Her urine
Recent laboratory results included a urine albumin/creati- ACR was 15 mg/mg.
nine ratio (ACR) of 65 mg/mg (normal , 17 mg/mg). Blood
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Fig. 2. Cumulative risk of the development of persistent proteinuria
or ESRD in IDDM siblings of index cases with diabetic nephropathy
(solid line) and without nephropathy (broken line). (Reprinted with
Fig. 1. Pedigree of the case family. Men are indicated by squares, permission from Ref. 6.)
women by circles. Filled squares and circles indicate diabetes. “1”
indicates presence of diabetic nephropathy and “2” indicates normoal-
buminuria.
Recent studies have demonstrated that susceptibility
to diabetic nephropathy clusters in families. In the most
well as in those with non-insulin dependent diabetes comprehensive study of diabetic nephropathy in families
mellitus (NIDDM) [1, 2]. While it is well established that with multiple cases of IDDM among siblings, Quinn et
uncontrolled diabetes underlies the development of this al found that the cumulative risk of diabetic nephropathy
complication [3, 4], newer evidence suggests that geneti- among the index cases and their IDDM siblings was
cally determined susceptibility to hyperglycemia-caused 35% after 30 years of diabetes [6]. The risk to siblings,
glomerular injury also is necessary. This possibility is however, was profoundly dependent on whether the in-
well illustrated by the case family, in which both siblings dex case had proteinuria. The cumulative risk of diabetic
had long-lasting uncontrolled diabetes but were discor- nephropathy was 71.5% if the index case had persisent
dant for diabetic nephropathy; only one, perhaps the one proteinuria, but only 25.4% if the index case had nor-
with genetic susceptibility, developed overt proteinuria.
moalbuminuria (Fig. 2). This difference in risk of nearly
Molecular characterization of genetic susceptibility
50%, depending on whether the index case had protein-would increase our understanding of the pathogenesis
uria, has been shown through simulation models to beof diabetic nephropathy and would provide diagnostic
much larger than can be attributed plausibly to familialtools for identifying susceptible patients so they could
clustering of environmental factors [7]. Therefore, onebe targeted for intensive control of hyperglycemia. Such
can infer that familial clustering of diabetic nephropathyknowledge also would guide us in developing new pre-
is most likely due to genetic factors [6]. Three otherventive and therapeutic programs. In this presentation,
studies have demonstrated statistically significant famil-I will review the evidence that genetic factors are in-
ial clustering of diabetic nephropathy, but the study de-volved in the development of diabetic nephropathy and
signs were not suitable for estimating the magnitude ofsummarize the current status of the hunt for genes for
the familial effect [8–10].diabetic nephropathy, first in IDDM and later in NIDDM.
Among Caucasoid patients with IDDM, the lifetime
Models of genetic susceptibilityrisk of persistent proteinuria is approximately 33%, with
Various models can be constructed to represent differ-the incidence reaching a peak during the second decade
ent theories about the pathogenesis of diabetic nephrop-of diabetes and declining thereafter [5]. This pattern
athy [11]. To be consistent with epidemiologic studies,suggests that only a subset of individuals with IDDM is
feasible models must assume that poor glycemic control,susceptible to the development of diabetic nephropathy.
or factors associated with it, are necessary but not suffi-Few new cases of proteinuria appear among patients
cient for the development of diabetic nephropathy. Towith long-lasting diabetes because most susceptible indi-
be sufficient, the cause must include genetic susceptibilityviduals have developed diabetic nephropathy earlier in
the course of the disease. that results from DNA sequence differences, hereafter
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Table 1. Models of genetic susceptibility to diabetic nephropathy
Major gene effect 5 poor glycemic control Xa One gene
Moderate gene effects 5 poor glycemic control X Several genes with similar additive effects (one major and several minor effects)
Polygenic effects 5 poor glycemic control X Many genes with small additive effects
a X, interaction (i.e., both must be present)
referred to as polymorphisms/mutations or disease alleles, risks for diabetic nephropathy in IDDM family members
having different degrees of relatedness (monozygoticin regulatory or structural parts of one or more genes.
For purposes of illustration, I will describe three mod- twins, siblings, and cousins), also has not been used be-
cause of a lack of data [14].els in which genetic susceptibility assumes a critical role,
although the genetic mechanisms are strikingly different Reasoning solely from the data of Quinn et al on the
lifetime risk of diabetic nephropathy in unrelated IDDM(Table 1). The first model, which assumes a major gene
effect, postulates that diabetic nephropathy develops as patients (35%) and the risk in IDDM siblings [6], we
attempted to identify models involving a single majora result of the interaction between poor glycemic control
and susceptibility to diabetic nephropathy due to poly- gene effect that would be compatible with a sibling recur-
rence risk of 71.5% if the index case had nephropathymorphisms in one gene. The second model, which assumes
moderate gene effects, postulates that diabetic nephrop- but only 25.4% if the index case did not [15, 16]. For
example, an autosomal dominant gene with a 20% dis-athy develops as a result of the interaction between poor
glycemic control and genetic susceptibility due to poly- ease allele frequency and full penetrance would imply a
36% lifetime risk in the population of individuals withmorphisms/mutations in any one of several genes. Dis-
ease alleles in each of these genes contribute indepen- IDDM, and risks of 66.2% and 19.0%, respectively, to
IDDM siblings of index cases with and without nephrop-dently and additively to susceptibility. However, the
appearance of the overall effect is influenced by the rela- athy. This result agrees well with the data of Quinn et
al, so an autosomal dominant model qualifies as onetive frequency of the disease alleles of these genes in
populations. If the disease alleles have similar frequencies, reasonable genetic model of nephropathy among indi-
viduals with IDDM. Similarly, an autosomal recessivethe effect of each of them will be moderate. If the disease
allele at one locus is much more frequent than those at model with a 60% disease allele frequency in the general
population also would account for the same lifetime riskother loci, the overall result could appear as a major
gene effect, with the other genes playing minor roles. The of nephropathy in IDDM and similar sibling risks, 64.0%
and 23.3%, depending on the presence or absence ofthird model, which assumes polygenic effects, postulates
proteinuria in the IDDM index case. This model, how-that poor glycemic control interacts with DNA sequence
ever, invokes an extremely high frequency of the diseasedifferences in many loci. Each locus is a minor contribu-
allele in the general population. In addition to these single-tor to the overall susceptibility to diabetic nephropathy.
gene models, the data of Quinn et al also are compatibleEach of these models can be developed in further
with models featuring moderate gene effects (Model 2)detail. For example, the disease allele in a putative gene
but not with those featuring polygenic effects (Model 3).can predispose to the development of diabetic nephropa-
For example, a model with two independent (additive)thy only in the homozygous state (recessive effect). Al-
genes with moderate effects, or a single major gene effectternatively, diabetic nephropathy can develop if patients
with a moderate polygenic contribution, can be hypothe-have poor glycemic control and only one copy of the
sized.putative disease allele (dominant effect). In addition,
Unfortunately, existing data on familial clustering ofalthough it will not be a subject of this presentation, the
diabetic nephropathy do not allow testing of more com-manifestation (penetrance) of a particular susceptibility
plicated models [11], in which different genes are in-genotype can depend on the intensity or the cumulative
volved in a predisposition to the onset of diabetic ne-exposure to hyperglycemia [3, 12].
phropathy and other genes are involved in its progressionEvidence for discriminating among the three possible
to overt proteinuria or ESRD. Those models can beunderlying genetic models is scant. The models have not
tested only if specific candidate genes have been hypoth-been examined by segregation analysis of family data
esized and examined.because appropriate IDDM families occur too rarely
[13]. To be useful for this purpose, families must have
Strategies for determining diabetic nephropathy genesparents and children affected with IDDM so that the
risk of developing diabetic nephropathy can be estimated Knowledge of which of the three major models is cor-
rect would be important for the search for diabetic ne-for various familial relationships. An alternative nonpar-
ametric approach, requiring only estimates of recurrence phropathy genes, as it would guide selection of the opti-
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Table 2. Study designs that can be used to search for genes for diabetic nephropathya
Effective if risk Effective if location
Study design to siblings: of the gene is: Effect detected Spurious results
Discordant sib pair (DSP)b .50% Undetermined or specific Major & moderate No
Concordant sib pair (CSP) ,50% Undetermined or specific Major & moderate No
Transmission disequilibrium testing (TDT) Irrelevant Specific Major-minor No
Case-control studyc Irrelevant Specific Major-minor Frequent
a From Refs. 15–17
b Abbreviations: DSP, two siblings with IDDM, one with nephropathy and the other with normoalbuminuria and at least 15 years of IDDM; CSP, two siblings
with IDDM and both with nephropathy; TDT, so-called trios: DN1 IDDM patients with diabetic nephropathy and their parents; DN2 IDDM patients without
nephropathy and with diabetes for at least 15 years and their parents
c Case-control study, a group of unrelated IDDM cases with diabetic nephropathy and a group of unrelated controls with IDDM for at least 15 years and with
normoalbuminuria
Table 3. Clinical characteristics of IDDM siblings discordant formal strategy and study designs for identifying the genes.
nephropathy in 56 families used for discordant sib pair analysisa
Two different strategies are available in a search for one
IDDM siblingsor more gene(s) responsible for susceptibility to diabetic
With DN Without DNnephropathy. The first strategy assumes that the nature,
Characteristic n 5 58 n 5 60as well as the location, of the putative gene is unknown;
Age at Dx of IDDMone aims to find some part of a human chromosome
(mean 6 SD in years) 11 6 8 15 6 8that contains the gene. After a chromosomal region is Duration of IDDM in 1993
identified, a specific gene will be sought. Only genes that (mean 6 SD in years) 26 6 9 22 6 9
% with persistent proteinuria 53 —have major or moderate effects can be identified through
% with high microalbuminuria 10 —this approach (Table 2). The second strategy is used if % with ESRD 37 —
a specific gene is suspected as a susceptibility gene. One Antihypertensive treatment (%) 60 13
Insulin dose in U (mean 6 SD)b 46 6 23 45 6 17attempts to find a disease allele and test its contribution
Average HbA1c in % (mean 6to the development of diabetic nephropathy. Under this SD) for period 1988–1994 9.8 6 2.3 8.8 6 1.8
assumption, one can examine a gene regardless of a Adapted from Ref. 18
whether it plays a major or minor role (Table 2). b All were treated with insulin within 2 years of diagnosis of diabetes
c Available for 36 DN2 and 46 DN1 siblings who are attending Joslin Clinic.
In total there were 66 DSPs: 31, 32 and 3 with two, one, and zero parents,Genome screening for major gene effects examined, respectively
Using the data reported by Quinn et al, we first assumed
that susceptibility to diabetic nephropathy in IDDM is
determined by a major gene effect. To identify that gene, majority were treated with antihypertensive drugs. By
we initiated a genome screening for a chromosomal re- design, all DN2 siblings had had diabetes for at least
gion containing a gene that has a major effect [18]. For 15 years and had normal urinary albumin excretion.
this purpose, we have used IDDM sibling pairs (sib pairs) Highly informative DNA markers are being used to
discordant (DSP) for diabetic nephropathy. This study genotype each human chromosome in these DSP fami-
design was selected because the risk of nephropathy to lies. So far, three chromosomal regions have been geno-
siblings of index cases with nephropathy was much typed and analyzed [18]. These regions, although a part
higher than 50%, and we demonstrated in a simulation of the whole genome screening, were selected first be-
study that in such circumstances DSPs are about four cause they contain genes encoding proteins of the renin-
times more efficient than concordant sib pairs [16]. angiotensin system: the genes for angiotensinogen (AGT),
Table 3 shows the clinical characteristics of the siblings angiotensin-I converting enzyme (ACE), and angioten-
in 56 DSP families assembled for this study [18]. In gen- sin II type-1 receptor (AT1). The results of multipoint
eral, DN2 and DN1 were similar with regard to age at linkage analysis are presented in Table 4.
onset of diabetes, diabetes duration, body weight, and We genotyped 66 DSP from the 56 families for two
insulin dose. The DN1 siblings had poorer glycemic markers at each region. Among these sib pairs discordant
control (higher HbA1c) than did DN2 siblings. The for diabetic nephropathy, there was no distortion in allele
mean HbA1c among DN2 siblings, however, was not sharing for markers flanking the AGT gene or the ACE
different from that in the total population of IDDM gene. The proportions sharing 0, 1, and 2 alleles was
patients attending the Joslin Clinic. At the time of exami- close to the expected 0.25, 0.50, 0.25 under the hypothesis
nation, 37% of the DN1 siblings had end-stage renal of no linkage. One therefore can conclude that neither
disease, and the rest had persistent proteinuria. The region contains a locus accounting for a major gene effect.
Results of multipoint linkage analysis for markersDN1 siblings also had elevated blood pressure, and the
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Table 4. Results of testing three chromosomal regions for evidence of a major gene effect using discordant sib pairs (DSP)a
Estimated allele sharingb
Examined region and markers #DSP z0 z1 z2 P
Angiotensinogen region on 1q
AGT 66 0.30 0.44 0.26 NS
D1S459 66 0.28 0.46 0.26 NS
Angiotensin I-converting-enzyme region on 17q
D17S807 66 0.28 0.49 0.23 NS
D17S795 66 0.28 0.50 0.22 NS
Angiotensin II type-1 receptor region on 3q
ATCA 66 0.530 0.356 0.114 ,0.0001
D3S1308 66 0.511 0.374 0.115 ,0.0002
a Adapted from Ref. 18
b z0, z1, z2 are the estimated probabilities of sharing 0, 1, or 2 alleles identity by descent (IBD) among sib pairs; expected probabilities if there is no linkage are
0.25, 0.50, and 0.25, respectively. NS, not significant
flanking the AT1 gene are strikingly different. For the
ATCA markers, which are located 15.5 kb downstream
from the 39 end of the AT1 gene, there was an excess
of 0 allele sharing (0.53 estimated probability as com-
pared with 0.25 expected) and a deficiency of those shar-
ing one allele (0.36 estimated probability as compared
to 0.50 expected) or 2 alleles (0.11 estimated probability
as compared to 0.25 expected). Similar results were ob-
tained for marker D3S1308 located one cM from the AT1
locus. The difference between estimated and expected
probabilities of shared alleles was highly statistically sig-
nificant for both markers. Note that, in contrast to a
concordant sib pair study in which increased allele shar-
ing is evidence of linkage, positive results in a discordant
sib pair study are characterized by diminished sharing.
As a result of these positive findings in the AT1 region,
Fig. 3. Lod score plot for linkage between diabetic nephropathy andwe extended the genotyping to include 8 additional poly- markers on chromosome 3q. Multipoint sib-pair analysis for 10 markers
morphic markers spanning a 60 cM region around the genotyped in 66 discordant sib pairs. (Reprinted with permission from
Ref. 18.)AT1 locus. Multipoint analysis on all 10 markers showed
evidence of significant linkage (Fig. 3). The peak maxi-
mum lod score of 3.1 (P 5 7.7 3 1025) occurred at the
ATCA locus, and the region of the chromosome over disequilibrium test (I will describe this test in a moment).
which the maximum lod score was within one unit of this A similar analysis was done with DN2 offspring to rule
peak value encompassed 20 cM. The latter, therefore, is out both segregation distortion and the effects of genes
the critical interval within which the putative major gene that predispose to IDDM. None of the alleles at the
responsible for susceptibility to diabetic nephropathy six bi-allelic polymorphisms examined was preferentially
presumably resides [18]. transmitted to DN1 or DN2 offspring. These results
The most obvious candidate gene for diabetic ne- indicate that DNA sequence differences in the AT1 gene
phropathy in this critical interval was the AT1 gene itself. do not contribute to the genetic susceptibility to diabetic
To investigate whether DNA sequence differences in nephropathy [18]. Allelic variation in another gene in
this 5 exon gene could explain the linkage results, we the vicinity of the AT1 locus, therefore, must be responsi-
sequenced all exons, splicing junctions, and 2600 bp of ble for the major gene effect. At present the nature and
the promoter region in six DSPs (6 index cases with precise location of that gene is unknown.
proteinuria and 6 of their siblings without proteinuria). Let me return to the original three models. The posi-
In addition to three previously reported polymorphisms, tive findings in the AT1 region might seem to be more
we found four new polymorphisms, three in the promoter compatible with the first model (major gene effect) than
region and one in exon 4. Alleles of these polymorphisms with the second (moderate gene effects) but such a con-
were assessed for non-random transmission from hetero- clusion is premature. As I said, if the disease allele at one
of the loci in the second model is particularly frequent inzygous parents to DN1 offspring using the transmission
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Table 5. Transmission of alleles from parents heterozygous for thea population, the overall result can appear as a major
M235T polymorphism in the angiotensinogen gene to
gene effect. At this juncture, replication of our study in DN1 and DN2 offspringa
other populations would be informative regardless of the
Allele transmitted
Nephropathy No. ofoutcome. Confirmation of our finding in another popula-
in offspring parentsb 235T 235Mtion not only would add to the justification for the large-
Total groupscale effort required to search this 20 cM critical region
Presentc 143 (100%) 76 (53%) 67 (47%)in order to clone the diabetic nephropathy susceptibility
Absentd 89 (100%) 38 (43%) 51 (57%)
gene, but might provide evidence that would narrow the Chi2 5 2.40 (1.d.f. P 5 0.12)
Men onlycritical interval to be searched. On the other hand, if the
Presentc 73 (100%) 41 (56%) 32 (44%)evidence of linkage in another population is absent or
Absentd 41 (100%) 13 (32%) 28 (61%)
weaker than in our population, such a finding would be Chi2 5 6.30 (1.d.f. P 5 0.012)
more compatible with the second model. The implication a Adapted from Ref. 31. In total there were 148 trios with IDDM offspring
with diabetic nephropathy and 93 trios with IDDM offspring without diabeticwould be that the relative contributions of the several
nephropathydisease loci in the second model vary among populations, b Only heterozygous parents were used. In addition there were 250 parents who
were homozygous for M allele or T allele and, by definition, are uninformative forand this heterogeneity would argue against pooling fami-
this analysislies from different populations in future studies. c All offspring had IDDM and persistent proteinuria or ESRD
d All offspring had IDDM for at least 15 years and had normoalbuminuriaAn important consideration in planning a replication
study is that sib pairs with IDDM discordant for diabetic
nephropathy might be several times as informative as
those concordant for diabetic nephropathy. For example,
groups have generally comparable allele distributions.to achieve power equal to the present study, more than
Others, however, have proposed a more sophisticated250 sib pairs with IDDM concordant for nephropathy
analysis that does not require a matched control group.would be required [16]. This number of concordant sib
The best known of these techniques is the transmissionpairs would be difficult to assemble because of the high
disequilibrium test (TDT) first proposed by Spielman etmortality rate in patients with nephropathy [1].
al in 1993 [17]. This test is a very specific method for
detecting major as well as minor gene effects and, unlikeExamination of minor gene effects
the case-control comparison, this study design is free ofThe results of the discordant sib pairs study led us to
bias due to population stratification. The latter propertyconclude that the regions around AGT and ACE do not
of the TDTs can be compared to the unbiased findingscontain a locus having a major gene effect on susceptibil-
obtained in randomized clinical trials. In the TDT, af-ity to diabetic nephropathy (Table 4). However, this study
fected and non-affected individuals and their parents aredesign is not sensitive enough to exclude these genes as
collected. Then for a gene being considered, an alleleminor contributors to susceptibility to diabetic nephrop-
thought to be involved in disease susceptibility is identi-athy. As Table 2 shows, a study design based on compari-
fied. Finally, using only parents who are heterozygoussons of the frequency of polymorphisms/mutations in
for the allele, transmission of the allele to affected andunrelated groups of cases and controls or the intrafami-
unaffected offspring is determined. A transmission fre-lial association of specific alleles with diabetic nephropa-
quency greater than 50% to the affected offspring sug-thy (the transmission disequilibrium test, TDT) is more
gests that the specific allele (or one in linkage disequilib-appropriate for such goals.
rium) increases disease susceptibility.A large number of case-control studies have been con-
Our group recently used the TDT approach to exam-ducted to test the contribution of polymorphisms in the
ine the role of certain alleles in the AGT and ACE genesAGT and ACE genes to the development of diabetic
in the development of diabetic nephropathy [abstract;nephropathy in IDDM [19–30]. Unfortunately, the re-
Freire et al, Diabetes 46(Suppl 1):70A, 1997] [31]. Forsults of these studies have been contradictory. These
this purpose we collected a large group of IDDM patientsdiscrepancies might indicate that the DNA sequence dif-
with diabetic nephropathy and their parents (163 DN1ferences examined have little or no effect. The positive
trios) and patients with IDDM duration of at least 15findings also might be due to unrecognized factors in
years but without any clinical evidence of nephropathythe population studied (population stratification). For
together with their parents (93 DN- trios).example, the ancestral origins of the patients with dia-
Table 5 shows the transmission of alleles from parentsbetic nephropathy might have been quite different from
heterozygous for the M235T polymorphism (methioninethose of the controls, so the different allele frequencies
substituted by threonine at codon 235) in the AGT genereflect that history rather than a relevance to the disease
to IDDM offspring with and without nephropathy [31].process. To address this shortcoming, some authors con-
From 143 heterozygous parents, allele T was transmittedduct an initial analysis at random locations throughout
the genome to determine whether the case and control 76 times (53%) to offspring with diabetic nephropathy.
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Table 6. Transmission of alleles from parents heterozygous for the I/D polymorphism in the angiotensin I converting-enzyme gene
to DN1 and DN2 offspringa
Allele transmitted:
McNemar’s test
Nephropathy in offspring No. of parentsb Insertion Deletion P
Total group
Presentc 173 (100%) 101 (58%) 72 (42%) ,0.05
Absentd 94 (100%) 43 (46%) 51 (54%) NSe
Chi2 5 3.914 (1.d.f. P , 0.05)
Duration of IDDM in cases
,23 years 55 (100%) 35 (64%) 20 (36%) ,0.05
23–28 years 57 (100%) 32 (56%) 25 (44%) NS
291 years 61 (100%) 34 (56%) 27 (44%) NS
a Adapted from Ref. 31. In total there were 163 trios with IDDM offspring with nephropathy and 93 trios with IDDM offspring without nephropathy
b Only heterozygous parents were used. In addition there were 248 parents who were homozygous for the insertion or deletion allele and, by definition, are
uninformative for this analysis
c All offspring had IDDM and persistent proteinuria or ESRD
d All offspring had IDDM for at least 15 years and had normoalbuminuria
e NS, not significant.
The same allele was transmitted to IDDM offspring with- according to duration of diabetes at the time of examina-
tion (abstract; Freire et al, ibid). The largest excess trans-out diabetic nephropathy 38 times from 89 heterozygous
parents (43%). The difference between the two groups mission of the insertion (64%, P , 0.05) was to offspring
with the shortest duration of diabetes. In the two otherwas not statistically significant (Chi2 5 2.40, 1.d.f. P 5
0.12). When the groups were stratified by gender, the duration groups, there was excess of transmission of the
insertion, but it was not significantly different from 50%.difference became significant in men (Chi2 5 6.30, 1.d.f.
P 5 0.012) (Table 5). This means that the T allele (threo- Since prevalence cases of diabetic nephropathy were
used to select families into the study, the interpretationnine at codon 235 in the AGT gene), found to be associ-
ated with essential hypertension in non-diabetics [32, of this last observation is ambiguous. For example, one
can postulate that the insertion contributes mainly to33], increases susceptibility to diabetic nephropathy but
only among men with IDDM. early-onset diabetic nephropathy but not to later onset.
Alternatively, individuals with the insertion who devel-Table 6 shows the transmission of alleles from parents
heterozygous for the insertion/deletion in the ACE gene oped diabetic nephropathy might be at higher risk of
early death and thus are not found in those with a longto IDDM offspring with and without nephropathy (ab-
stract; Freire et al, ibid). From 173 heterozygous parents duration of diabetes. The latter interpretation seems to
be consistent with observations that homozygotes forof offspring with nephropathy, the insertion was trans-
mitted 101 times (58%) and the deletion was transmitted the insertion allele have less chance of surviving to old
age than do homozygotes for the deletion allele [35–37].72 times (42%). These frequencies are significantly differ-
ent from the expected 50% using McNemar’s test (P ,
Future studies in IDDM0.05). From 94 heterozygous parents of offspring without
diabetic nephropathy, the insertion was transmitted 43 The hunt for genes contributing to the development
times (46%) and the deletion was transmitted 51 times of diabetic nephropathy has just begun. Our research so
(54%). This difference was not significantly different far has provided evidence that at least one major gene
from 50%. In comparing the frequency of transmission effect on chromosome 3q contributes to the development
of the insertion allele to the two groups of offspring, how- of diabetic nephropathy in IDDM. In addition, we found
that certain polymorphisms in the AGT and ACE genesever, a significant difference was found (Chi2 5 3.914;
1.d.f. P , 0.05). Similar results were obtained in men make a minor contribution to the occurrence of this com-
plication. Let us consider future endeavors that shouldand women. These data provide strong evidence that
the insertion (or an unknown DNA sequence difference lead to the identification of the genes (as well as disease
alleles) accounting for genetic susceptibility to diabeticlinked with it) contributes to increased susceptibility to
diabetic nephropathy, not the deletion, as was shown in nephropathy.
The evidence for a major susceptibility locus on chro-some of the case-control studies [24, 29, 30]. Interestingly,
in a recent prospective study, the insertion was the risk mosome 3q (in the vicinity of the AT1 locus) that predis-
poses Caucasoids with IDDM to diabetic nephropathyallele for the development of microalbuminuria [34].
Table 6 also shows the transmission of insertion/dele- substantiates the growing body of previously circumstan-
tial evidence of a genetic basis for diabetic nephropathy.tion alleles from heterozygous parent to IDDM offspring
with diabetic nephropathy grouped into three categories This new evidence will fuel an interest in the search for
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additional nephropathy gene(s) using a genome screen. rapidity of progression [53]. For example, in Table 6
one could consider patients who developed proteinuriaThe goal will be to find all chromosomal regions that
contain loci with major, and possibly moderate, effects during the first 22 years of IDDM as “rapid” progressors.
Those with proteinuria and IDDM duration greater thanon susceptibility to nephropathy.
Our chromosome 3q findings need to be replicated in 22 years can be considered “slow” progressors. One can
infer from the data in Table 6 that carriers of the insertiondifferent populations before significant effort is directed
toward the identification of a susceptibility gene in this allele in the ACE gene are susceptible to the rapid devel-
opment of diabetic nephropathy. This hypothesis, how-region. Positive findings in another collection of families
not only would confirm our results but also could yield ever, must be investigated in a prospective study to ex-
clude a survival bias arising, for example, from a higherresults that would narrow the critical region. Unfortu-
nately, there are no other simple approaches to narrowing mortality rate among carriers of the insertion so they are
underrepresented among cases with long-duration IDDM.the critical region of 20 cM to a manageable size so that
all genes in the region can be identified and examined Once associations are established between certain al-
leles in specific genes and the development of diabeticfor their involvement in susceptibility to nephropathy
using the TDT method. The task of cloning the putative nephropathy, one must find the mechanisms through
which these DNA sequence differences lead to an in-gene through the positional candidate approach [38] will
be facilitated, however, by the development of physical creased risk of diabetic nephropathy. This search in-
volves identification of the true disease allele and iden-and transcript maps of the critical region on chromosome
3q as an outcome of the Human Genome Project. tification of the biologic mechanism through which
the putative disease allele affects the disease process.In addition to the search for major loci through ge-
nome screening, efforts at testing specific candidate genes/ Whereas the first is determined by doing more genetic
studies in humans, the second can be studied in variouscandidate pathways will continue. Genes encoding pro-
teins involved in renal hemodynamics [39–41], activation biologic models as well as in humans. I will use the
associations found between diabetic nephropathy andof protein kinase C [42, 43], oxidative stress [44–46], and
formation and degradation of advanced glycation end certain alleles in the AGT and ACE genes (Tables 5 &
6) as examples to illustrate the experimental challenges.products [47–49] remain to be examined for DNA se-
quence differences and then examined for association Although we showed that the T235 allele in the AGT
gene is associated with diabetic nephropathy, particu-with alternative phenotyes of diabetic nephropathy. As
of now, a large number of candidate genes have been larly among men, it is unclear whether this allele has a
biologic role. Jeunemaitre and colleagues recently con-examined using case-control studies [50], but the con-
flicting results make it clear that more reliable study ducted an extensive investigation of polymorphisms at
the AGT locus in two populations, French and Japanesedesigns such as the TDT must be employed.
In all our studies, persistent proteinuria was taken as [54]. They found 10 bi-allelic polymorphisms in the whole
gene. Among them, the M235T polymorphism and thethe phenotype of diabetic nephropathy. Although clini-
cal and epidemiologic data support the appropriateness G to A substitution located at position -6 upstream of
the transcription initiation site occurred with the sameof this choice [5], other possibilities for phenotypic classi-
fications should be considered. For example, DNA se- frequency and in complete linkage disequilibrium in both
populations. That is, the G and A alleles at position -6quence differences in one set of genes might increase
susceptibility to the development of microalbuminuria, are virtually synonymous with the M and T alleles at
codon 235, respectively.and another set could be involved in its progression to
overt proteinuria or progression to ESRD. The question arises, is the real disease allele the A at
position -6 or the T at codon 235? Whereas the latterRecently, Freedman et al put forward a hypothesis
that a specific genetic susceptibility predisposes one to does not have any obvious biologic implication, recently
Inoue et al have shown that the substitution of A for Gthe development of ESRD [51]. These authors came
to this conclusion by studying large African-American at position -6 increases the basal transcription rate of
AGT gene in COS-1 cells [55]. This increased transcrip-families with clustering of ESRD. The causes leading to
ESRD within the same family varied, however: NIDDM, tion rate suggests that carriers of the A allele have higher
levels of angiotensinogen in both the serum and thehypertension, glomerulonephritis, or HIV. The notion
of genetic susceptibility to ESRD is supported by genetic kidney and an increased availability of substrate for the
formation of angiotensin II. Such an effect might accountstudies in animal models. For example, in the fawn-
hooded rat model, the majority of the risk for the devel- for the observation that homozygotes for 235TT (and at
the same time AA at position -6) have blunted renalopment of ESRD appeared to be linked to two novel
genes on rat chromosome 1 called Rf-1 and Rf-2 [52]. blood flow responses to exogenous angiotensin II (Ang
II) [56]. In other words, these affected individuals couldAn alternative approach to a classification based on
the stages of diabetic nephropathy is one based on the not respond because they already had excess intrarenal
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formation of Ang II. The fact that the latter occurred relative. Similar observations were made in Caucasoid
NIDDM families. Diabetic nephropathy is more preva-only in men is in agreement with the data in Table 5.
The explanation for the association between the inser- lent among diabetic siblings of NIDDM index cases with
diabetic nephropathy than among diabetic siblings oftion/deletion in the ACE gene and the development of
diabetic nephropathy is not clear. The following issues NIDDM index cases without nephropathy [abstract; Ca-
nani et al, Diabetes 46(Suppl 1):70A, 1997] [65]. Usingremain to be resolved: (1) confirmation of our finding
that the insertion rather than the deletion is the marker white families with multiple NIDDM members, Fogarty
et al performed segregation analyses to examine theof increased susceptibility. (2) identification of the true
disease allele that is linked with the insertion allele [57, mode of inheritance of diabetic nephropathy. The data
were compatible with a major gene effect with a rela-58]. After sequencing the exons and promoter region of
the ACE gene from two individuals homozygous for tively frequent disease allele [abstract; Fogarty et al,
Diabetes 47(Suppl 1):A12, 1998]. The conclusion of thisthe insertion and two individuals homozygous for the
deletion, Villard and colleagues were unable to find a study is similar to that obtained by Quinn et al in white
IDDM families [6].DNA sequence difference that could be considered bio-
logically important [58]. Therefore, other DNA sequence Although familial clustering of diabetic nephropathy
has been demonstrated in all the populations studied,differences that have demonstrable biologic functions
must be closely associated with the insertion. These dif- significant differences exist in the magnitude of the risk
for nephropathy in NIDDM in these racial groups. Theferences might be located in the first 12 introns or a
distant promoter, or they could be in genes flanking the most frequent occurrence of diabetic nephropathy is in
Native Americans. For example, in Pima Indians withACE locus. (3) Although the insertion is associated with
decreased serum ACE levels [58], it is not clear that NIDDM, the cumulative incidence of persistent protein-
uria after 25 years of diabetes is 80% [66]. The risk insusceptibility to diabetic nephropathy is influenced by
the ACE levels. For example, homozygotes for the inser- African-Americans with NIDDM is intermediate; risk
seems lowest in whites with NIDDM [67–69]. In whites,tion are more insulin resistant than are homozygotes for
the deletion [59, 60]. The pathobiology underlying this the cumulative risk after 20 years of diabetes is approxi-
mately 30% [69, 70]. The question arises whether thedifference is not clear. Similarly unknown is the mecha-
nism responsible for abnormalities in renal hemodynam- differences among races are due to different frequencies
of disease alleles at the same loci, or whether differentics, specifically in IDDM patients homozygous for the
insertion [61]. loci are responsible for the susceptibility in each of these
populations.
Genetic susceptibility to nephropathy in NIDDM In a large number of Pima Indian families with
NIDDM, a genome screen was carried out to identifyDiabetic nephropathy is also the major complication
in non-insulin-dependent diabetes mellitus, and can re- major loci for NIDDM. As a substudy, an analysis was
performed in families with two or more NIDDM siblingssult in premature death due to coronary artery disease
or lead to ESRD [2, 62]. Does genetic susceptibility to concordant for diabetic nephropathy [71]. There were
99 such sib pairs in 56 families. Using a 6 cM screen,diabetic nephropathy play an important role in NIDDM?
If so, are the genes involved the same as in IDDM? four chromosomal regions were identified that showed
some evidence for linkage with diabetic nephropathy:Over the last few years, it has been shown that diabetic
nephropathy clusters in NIDDM families. In Pima Indi- 3q (P , 0.05), 7q (P , 0.001), 9q (P , 0.01), and 20q
(P , 0.01). Coming from a total genome screen whereans, Pettitt et al reported the risk of nephropathy in
diabetic offspring of diabetic parents [63]. Proteinuria the number of statistical comparisons is large, none of
these P values can be considered as significant evidenceoccurred in 14% of diabetic offspring if neither diabetic
parent had proteinuria, 23% if one diabetic parent had for linkage. Perhaps some of the linkage results would
be significant if more sib pairs were examined. The chro-proteinuria, and 46% if both diabetic parents had pro-
teinuria. Recently the study was enlarged, and segrega- mosome 3q finding in Pima Indians was localized about
20 cM telomeric of the peak maximum lod score in ourtion analyses were performed. The family data were com-
patible with a major gene effect; a very frequent disease study in IDDM (Fig. 3). This large distance makes it
difficult to assess the likelihood that the two studies pointallele was responsible for susceptibility to nephropathy
in Pima Indians with NIDDM (abstract; Imperatore et to the same major locus of susceptibility to diabetic ne-
phropathy. Such a possibility needs to be investigatedal, Am J Hum Genet 61:A280, 1997). Familial clustering
of ESRD in African-Americans was reported by Freed- further.
Yu et al studied 38 African-American sib pairs concor-man et al [51, 64]. Among index cases with NIDDM
and ESRD, 37% reported a close relative with ESRD. dant for both NIDDM and diabetic nephropathy [72].
They examined specifically the ATCA marker on chro-Among age- and gender-matched NIDDM individuals
without nephropathy, only 7% reported ESRD in a close mosome 3q, which is 15 kb 39 from the AT1 locus, and
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did not find any evidence for linkage. In that study, nega- QUESTIONS AND ANSWERS
tive results also were obtained for other loci that contain Dr. John T. Harrington (Dean, Tufts University
AGT, ACE, and kallikrein genes. In the same collection School of Medicine, Boston, Massachusetts): A recent
of concordant ESRD sib pairs (expanded to 58 sib pairs), publication from Sweden and the results of the DCCT
Freedman et al examined linkage between ESRD and have shown that the risk of nephropathy can be reduced
a renal failure susceptibility gene (Rf-1), previously iden- or significantly delayed by improved glycemic control
tified in the fawn-hooded rat [51]. They found no evidence [3, 77]. Doesn’t this information suggest that glycemic
for linkage between ESRD and markers on 10q where control is the most important factor in the development
the human homologue of Rf-1 is localized (abstract; of diabetic nephropathy and argue against a major role
Freedman et al, J Am Soc Nephrol 8:67A, 1997). However, for genetic susceptibility?
because of the small number of concordant sib pairs, the Dr. Krolewski: Diabetic nephropathy does not de-
negative results from all these studies do not exclude velop in the absence of hyperglycemia. However, in the
the possibility of a susceptibility gene with a moderate presence of poorly controlled diabetes, less than one-half
or even major effect within any of the examined loci. of the patients with IDDM develop this complication. In
Just as in IDDM, case-control studies have been done our recent study at Joslin, we found that among individu-
to examine various candidate genes for diabetic ne- als with very poorly controlled diabetes, the lifetime risk
phropathy in NIDDM. Genes encoding the renin-angio- of ESRD was only 35% [78]. Therefore, poor diabetes
tensin system have been studied extensively, but the control is necessary but not sufficient for the develop-
results are inconclusive [73–75]. In contrast to IDDM ment of diabetic nephropathy. Other factors exist that
patients with diabetic nephropathy whose parents are interact with poor glycemic control to produce nephrop-
usually still living, most NIDDM patients with nephropa- athy. I have shown evidence that one additional factor
thy do not have living parents. Therefore, it is not possi- is genetic susceptibility.
ble to study candidate genes using the TDT method. New Dr. Mark E. Williams (Director of Dialysis, Division
study designs have been proposed recently to examine
of Nephrology, Beth Israel Deaconess Hospital, West
allelic associations that rely on the examination of af-
Campus, Boston): If we improve diabetes control andfected and unaffected siblings [76].
reduce the risk of diabetic nephropathy as the DCCT
demonstrated, then what could be the value of knowingSummary and conclusions
the genes for diabetic nephropathy?Evidence that genetic susceptibility plays a major role
Dr. Krolewski: The notion that every patient within the development of diabetic nephropathy in patients
IDDM can control diabetes well enough is erroneous.with both types of diabetes is strong, and the search has
With current therapies, few patients are able to maintainbegun for the susceptibility genes. The success of this
normoglycemia (HbA1c , 6.1%) and only one-half ofendeavor is critically dependent on the availability of fami-
IDDM patients are able to maintain good-to-fair gly-lies with diabetic nephropathy. The case family discussed
cemic control (HbA1c , 8.1%) [3, 4, 12]. In the lattertoday is an example of a “discordant sib-pair” family.
group, the lifetime risk of ESRD is still about 10% [78].New study designs that are based on a collection of such
Moreover, beyond the world of diabetes, it is possiblefamilies are particularly effective in the search for a gene
that the genes that predispose patients to diabetic ne-with a major effect. With this study design we have al-
phropathy also are the genes that predispose people toready identified a region on the long arm of chromosome 3
progressive renal disease in the presence of other disor-in the vicinity of the angiotensin II type-1 receptor gene
ders. Such a finding would be more than a breakthrough.that harbors a locus with a major effect. Once our find-
Dr. Harrington: I have a broader biologic question.ings are confirmed, a positional candidate gene approach
Is there any speculation as to why or how a gene forwill be undertaken to identify the putative locus. In addi-
susceptibility to diabetic nephropathy, or progressive re-tion, evidence exists for genes with minor effects. Several
nal disease, arose in the first place? It does not seem tocandidate genes have been studied using a case-control
fit any evolutionary theory of natural selection.study design. The results have been conflicting, most
Dr. Krolewski: I can think of two possibilities. As Ilikely because of the vulnerability of case-control studies
said, the fact that about 35% of Caucasoids with diabetesto various selection biases. To avoid this problem, a
develop diabetic nephropathy means that the alleles re-family-based study (patient with diabetic nephropathy
sponsible for susceptibility to diabetic nephropathy—Iand both parents) that tests segregation of risk alleles
will call them nephropathy alleles—must be quite com-from parents to offspring should become the preferred
mon. This implies that either the alleles are very old, atstudy design. With this approach, we have demonstrated
least hundreds of thousands of years, and their effect isminor effects of the insertion allele in the ACE gene
neutral in the absence of hyperglycemia, or the allelesand the T-allele at position 235 in the angiotensinogen
gene on the development of diabetic nephropathy. are much younger but they became common because of
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some survival advantage. In the presence of hyperglyce- increased activity of the Na1/H1 exchanger in lympho-
blasts and fibroblasts of patients with diabetic nephropa-mia, a totally new environment for the body, the postu-
lated alleles might take on new functions, or the pre- thy or essential hypertension was associated with an in-
creased intracellular signal transduction via pertussis-viously advantageous function might be changed, either
change leading to the development of diabetic nephropa- toxin-sensitive G proteins [91, 92]. This enhanced signal
transduction was associated with a novel polymorphismthy. I do not know which scenario is true.
Dr. Nicolaos E. Madias: (Chief, Division of Nephrol- C825T in exon 10 of the gene encoding the b3 subunit of
heterotrimeric G proteins [93]. The T-allele is associatedogy, New England Medical Center, Boston): You as well
as Viberti showed that IDDM individuals with hyperten- with the occurrence of a splice variant in which the nucle-
otides 498-620 of exon 9 are deleted. This in-frame dele-sive parents are at particularly high risk for diabetic
nephropathy [79, 80]. Do you think that susceptibility tion was observed more frequently in patients with essen-
tial hypertension in comparison with individuals withto diabetic nephropathy is the same as susceptibility to
essential hypertension? normal blood pressure [93]. We tested the association
between the C825T polymorphism in the b3 subunit ofDr. Krolewski: I do not think that it is the same,
but certainly they overlap. Essential hypertension has a the G protein and the development of diabetic nephropa-
thy in IDDM. No association was found in a large case-significant genetic component, and most likely many
genes are involved, each having a minor effect. We postu- control study as well as in a large family-based study
[94]. These results practically exclude this polymorphismlate that the expression and penetrance of one of these
minor genes for essential hypertension is changed in as being involved in the development of diabetic ne-
phropathy. I would like to emphasize that everything thatthe presence of hyperglycemia such that carriers of that
disease allele, which must be a common one, would de- I said was about Na1/H1 exchanger #1; little research has
been done on other isoforms of the exchanger.velop diabetic nephropathy together with their hyperten-
sion. Normoglycemic carriers, on the other hand, would Dr. Ramesh C. Nayak (Department of Physiology,
Tufts University School of Medicine): The data regardingjust develop hypertension—perhaps not all of them, but
a proportion of them would. The clinical and epidemio- the insertion/deletion polymorphism in the ACE gene
are very confusing. How can we make sense out of sologic studies in support of this hypothesis have already
been done. They include our own studies [79, 81, 82] many contrasting findings?
Dr. Krolewski: I agree with you. The simplest solu-and those of Viberti [80, 83, 84] as well as several recent
ones [85, 86]. To test this hypothesis further, we must tion is to take the results of the case-control studies not
very seriously. However, some inferences can be madefind the genes for diabetic nephropathy.
Dr. Madias: Overactivity of the Na1/H1 exchanger from the data from these studies. Since the results are
so variable, one can conclude that the effect of the ACEhas been the most consistent finding in individuals who
develop diabetic nephropathy [82, 84, 87, 88]. Similar gene on the development of diabetic nephropathy, or its
progression, is rather small and that it can be easilyobservations have been made in individuals with essen-
tial hypertension [89, 90]. Do you think that DNA se- obscured by selection or survival biases or population
stratification. The only way to determine the true effectquence differences in the Na1/H1 exchanger genes or
in genes regulating these exchangers might contribute of this polymorphism on the development of diabetic
nephropathy is through prospective observations andto the susceptibility to diabetic nephropathy?
Dr. Krolewski: High activity of the Na1/H1 ex- family-based studies such as the TDT. As I demon-
strated, quite different conclusions were derived fromchanger, perhaps, is genetically determined. However,
polymorphisms in the gene encoding for the Na1/H1 the family-based study. However, our finding that the
insertion is the marker of susceptibility to the develop-exchanger #1, the only isoform expressed in lympho-
blasts, are not responsible for this phenotype [82] (Kro- ment of early diabetic nephropathy must be confirmed
in other family-based studies.lewski et al, unpublished observations). Recent studies
have indicated that increased activity of the Na1/H1 Dr. Harrington: Would you define a cM, and how
many genes are there in the critical region on chromo-exchanger in cells obtained from patients with nephropa-
thy correlated with an increased proliferation of the cells some 3q?
Dr. Krolewski: A centimorgan (cM) is a measure ofin comparison with cells obtained from IDDM patients
with long-standing diabetes and no nephropathy [84, 88]. the relative distance between genes on a chromosome.
A crossover frequency of 1% between genes equals 1Whereas the increased exchanger activity can be blocked
by ethyl-isopropylamiloride (EIPA), the increased pro- cM. On average, 1 cM contains about 1,000,000 base
pairs. The critical interval on chromosome 3q is aboutliferation cannot [89]. This difference indicates that these
phenomena can be independent phenotypes or pleiotro- 20 cM and presumably contains 200 to 400 genes, most
of which are currently unknown genes.pic effects of another gene that is unknown at present.
Recently, Siffert and colleagues have shown that the Dr. Madias: How certain are you that the gene for
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angiotensin II type-1 receptor is not involved in suscepti- can postulate that this region might contain a gene that
makes Pima Indians resistant to diabetic nephropathy.bility to diabetic nephropathy? Your group published a
case-control study in which you reported positive find- Dr. Geetha Narayan (Division of Nephrology, St.
Elizabeth’s Hospital, Brighton, Massachusetts): In one ofings [95].
Dr. Krolewski: You are right. We published a paper your earlier publications, you showed that the cumula-
tive incidence of proliferative retinopathy seems to in-in which we showed an association between one of the
polymorphisms in the angiotensin II type-1 receptor and crease continually with duration of diabetes, whereas the
incidence of proteinuria appears to plateau after 25 todiabetic nephropathy, but only among individuals with
poor glycemic control [95]. However, in a recent TDT 30 years of diabetes [96]. So after 40 years of diabetes,
35% of IDDM patients have proteinuria, whereas 75%study, we could not find any association with the pre-
viously studied polymorphism or with 6 other polymor- have proliferative retinopathy. How can there be such
a discrepancy if both complications are an expression ofphisms in this gene [18]. We put much more trust in the
results from the family-based study. the same underlying disease process in small vessels?
How do you incorporate this discrepancy into geneticDr. Williams: I have noticed that the siblings without
diabetic nephropathy have better glycemic control than susceptibility?
Dr. Krolewski: Although authors have tried to finddo the siblings with diabetic nephropathy. Does this dif-
ference have any impact on the interpretation of the a unified pathogenetic mechanism for the development
of late diabetic complications, data have been inconsis-findings of your sib pair analysis?
Dr. Krolewski: Yes, it does. Since not everybody tent with this hypothesis. I am strongly convinced that
the causes of diabetic nephropathy, retinopathy, andamong the siblings without diabetic nephropathy had poor
glycemic control, however, we can expect that several neuropathy are different. The differences in the cumula-
tive risk of these complications according to durationindividuals in that group are carriers of the susceptibility
gene for nephropathy but have not shown it because of of diabetes simply reflect their different etiologies. The
genetic susceptibility I discussed is specific for diabetictheir good glycemic control. If so, this “contamination”
could have artifactually elevated the frequencies of shar- nephropathy. I am not sure that there is a genetic suscep-
tibility to diabetic retinopathy. Since the lifetime risking 1 or 2 alleles in Table 3 and therefore reduced the
lod score for our findings. for proliferative retinopathy in IDDM is high (75% or
higher) one might postulate only the existence of lociDr. Madias: You spoke with enthusiasm about the
discordant sib pair study design. Do you see any value that make individuals resistant to this complication.
of collecting concordant sib pairs for future studies on
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